{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:01:57Z","timestamp":1790870517754,"version":"4.1.0"},"reference-count":42,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Although an increasing number of cases of new-onset pemphigus have been reported following drug exposure or vaccination, the available evidence remains fragmented and distinguishing true trigger-associated disease from coincidental onset continues to represent a major clinical challenge. We performed a systematic review to evaluate the available evidence on drug- and vaccine-associated new-onset pemphigus and to compare their clinical characteristics, management, and outcomes. Methods: This systematic review was conducted according to the PRISMA 2020 statement and prospectively registered in PROSPERO (CRD420261307622). PubMed was searched from database inception to 30 April 2026. Studies reporting individual patients with new-onset pemphigus temporally associated with drug exposure or vaccination were included. Demographic, clinical, immunopathological, therapeutic, and outcome data were extracted and synthesized descriptively because of the anticipated heterogeneity of the available evidence. Results: A total of 20 drug-associated and 26 vaccine-associated cases identified from primary reports were included in the descriptive synthesis. Drug-associated cases demonstrated marked heterogeneity in the implicated agents, broader clinical variability, and a longer median latency, with frequent clinical improvement following withdrawal of the suspected drug when reported. In contrast, vaccine-associated cases occurred predominantly after SARS-CoV-2 vaccination, displayed a substantially shorter latency, and were mainly represented by pemphigus vulgaris and pemphigus foliaceus. Across both groups, systemic corticosteroids constituted the mainstay of treatment, with generally favorable outcomes among patients with available follow-up. However, the available evidence consisted almost exclusively of case reports and small case series, precluding reliable assessment of incidence or causality. Conclusions: Current evidence suggests that drugs and vaccines may act as potential triggers of new-onset pemphigus in susceptible individuals; however, the strength of evidence differs substantially between the two settings. Drug-associated cases generally provide more convincing clinical support for a trigger-related mechanism, whereas vaccine-associated cases require more cautious interpretation because temporal association alone cannot establish causality. Standardized case reporting, prospective pharmacovigilance, and mechanistic studies are needed to strengthen causal inference and improve the recognition and management of trigger-associated pemphigus.<\/jats:p>","DOI":"10.3390\/vaccines14090828","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:35:28Z","timestamp":1790868928000},"page":"828","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New-Onset Pemphigus Following Drug Exposure and Vaccination: A Systematic Review of Reported Cases"],"prefix":"10.3390","volume":"14","author":[{"given":"Gabriele","family":"Poddine","sequence":"first","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale Stefani, 1, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6163-6921","authenticated-orcid":false,"given":"Francesco","family":"Bellinato","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale Stefani, 1, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale Stefani, 1, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-0493","authenticated-orcid":false,"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale Stefani, 1, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: Recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: Pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev. Pathol. Mech. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","unstructured":"Maronese, C.A., Genovese, G., Moltrasio, C., Cozzani, E., and Marzano, A.V. (2024). Pemphigus: Trigger and predisposing factors. Front. Med., 11."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"107299","DOI":"10.1016\/j.intimp.2020.107299","article-title":"Drug-induced pemphigus: A systematic review of 170 patients","volume":"92","author":"Ghaedi","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clindermatol.2011.01.016","article-title":"Drug-induced pemphigus","volume":"29","author":"Brenner","year":"2011","journal-title":"Clin. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Martora, F., Battista, T., Potestio, L., Napolitano, M., Patruno, C., Megna, M., and D\u2019agostino, M. (2023). Pemphigus and bullous pemphigoid following COVID-19 vaccination: A systematic review. Viruses, 16.","DOI":"10.3390\/v16121896"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigus: A review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1256","DOI":"10.1111\/jdv.19271","article-title":"New-onset pemphigus vulgaris and pemphigus foliaceus following COVID-19 infection and vaccination: Systematic review of case reports and a causal hypothesis","volume":"37","author":"Petti","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"bmj"},{"key":"ref_11","first-page":"2127","article-title":"Methodological quality of case reports and case series: The Joanna Briggs Institute critical appraisal tools","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s43556-025-00272-9","article-title":"Autoimmune bullous diseases: Pathogenesis and clinical management","volume":"6","author":"Feng","year":"2025","journal-title":"Mol. Biomed."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: A comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches","volume":"54","author":"Pollmann","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.det.2011.03.020","article-title":"The genetics of pemphigus","volume":"29","author":"Sinha","year":"2011","journal-title":"Dermatol. Clin."},{"key":"ref_15","first-page":"389","article-title":"Environmental triggers of pemphigus vulgaris","volume":"94","author":"Valenzuela","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"ref_16","first-page":"620","article-title":"Pemphigus and autoimmunity","volume":"7","author":"Sagi","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"ref_17","first-page":"420","article-title":"Autoimmune blistering diseases associated with novel targeted anti-cancer therapies and immune checkpoint inhibitors","volume":"84","author":"Asztalos","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","first-page":"2012","article-title":"Characteristics of post-vaccination autoimmune blistering diseases: A comprehensive literature analysis","volume":"36","author":"Solimani","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Amber, K.T., Valdebran, S., Kridin, K., and Grando, S.A. (2018). Pathogenesis and clinical significance of non-desmoglein autoantibodies in pemphigus vulgaris. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01190"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-011-8294-7","article-title":"Molecular mimicry as a mechanism of autoimmune disease","volume":"42","author":"Cusick","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"108480","DOI":"10.1016\/j.clim.2020.108480","article-title":"Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases","volume":"217","author":"Vojdani","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_23","first-page":"305","article-title":"Drug-induced pemphigus: Pathogenesis and clinical forms","volume":"35","author":"Ruocco","year":"1996","journal-title":"Int. J. Dermatol."},{"key":"ref_24","first-page":"1","article-title":"Immunopathogenesis of pemphigus","volume":"135","author":"Culton","year":"2015","journal-title":"J. Invest Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: Overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol. Res."},{"key":"ref_26","first-page":"782413","article-title":"Advanced diagnostic tools for autoimmune blistering diseases","volume":"8","author":"Calabresi","year":"2021","journal-title":"Fron. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions associated with immune checkpoint inhibitors: A clinical guide","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_30","first-page":"642","article-title":"Pemphigus induced by biologic agents and targeted therapies: A systematic review","volume":"33","author":"Ellis","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_31","first-page":"180","article-title":"Immune checkpoint inhibitors in dermatology: Adverse event profiles and cutaneous toxicity management","volume":"148","author":"Quaglino","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_32","first-page":"295","article-title":"The environment and disease: Association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc. R Soc. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_34","first-page":"307","article-title":"Vaccination and autoimmune diseases: What have we learned from COVID-19?","volume":"18","author":"Hausmann","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_35","first-page":"611","article-title":"Vaccine-induced autoimmunity: The role of adjuvants and molecular mimicry","volume":"14","author":"Pellegrino","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0140-6736(03)14802-7","article-title":"Vaccination and autoimmune disease: What is the evidence?","volume":"362","author":"Wraith","year":"2003","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.phrs.2015.08.003","article-title":"Vaccines, adjuvants and autoimmunity","volume":"100","author":"Baker","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_38","first-page":"280","article-title":"Autoimmune post-COVID-19 vaccination syndromes: A review","volume":"34","author":"Jara","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"B8","DOI":"10.1016\/j.vaccine.2020.01.100","article-title":"ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations","volume":"38","author":"Sturkenboom","year":"2020","journal-title":"Vaccine"},{"key":"ref_40","first-page":"n1245","article-title":"COVID-19 vaccines and autoimmune adverse events: Pharmacovigilance perspectives","volume":"373","author":"Wise","year":"2021","journal-title":"bmj"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","article-title":"Methods for assessing causality in adverse drug reactions: A systematic review","volume":"31","author":"Agbabiaka","year":"2008","journal-title":"Drug Saf."},{"key":"ref_42","first-page":"S14","article-title":"Biologically plausible mechanisms of adverse events following immunization: A guide for pharmacovigilance","volume":"20","author":"Halsey","year":"2002","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/828\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:36:39Z","timestamp":1790868999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090828"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090828","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]}}}